Network meta-analysis
Constipation
Overweight or obesity without diabetes (adults)
longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)
44
Randomized trials
26
Treatments
19,747
Participants
3,535
Events
In plain language
Across 44 trials with 19,747 participants, 1 of 25 treatments had a clearly better result than placebo on constipation, 8 a clearly worse one, and for 16 the evidence could not tell them apart from placebo. The most favorable estimate was for Ct388 sc: hazard ratio (from event counts) 0.20 (95% credible interval 0.02 to 1.88).
Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Effects compared with Placebo
Hazard ratio (from event counts). Lower values favor the treatment.
| Treatment | Bayesian HR (95% CrI) | 95% prediction interval | Frequentist HR (95% CI) | Verdict |
|---|---|---|---|---|
| Ct388 sc CT388_SC | 0.20 (0.02 to 1.88) | 0.02 to 2.02 | Unclear | |
| Standard care or no added treatment STANDARD_CARE | 0.23 (0.09 to 0.51) | 0.08 to 0.63 | Better | |
| Bimagrumab OTHER_ACTIVE_bimagrumab | 0.53 (0.12 to 1.83) | 0.11 to 2.07 | Unclear | |
| Exenatide injection EXEN_SC | 0.56 (0.01 to 48.36) | 0.01 to 51.51 | Unclear | |
| Lifestyle intervention (randomized arm) LIFESTYLE | 0.61 (0.01 to 41.21) | 0.01 to 41.88 | Unclear | |
| Orlistat ORLISTAT | 0.86 (0.31 to 2.14) | 0.26 to 2.50 | Unclear | |
| Danuglipron tablet DANU_PO | 1.32 (0.34 to 7.94) | 0.30 to 8.97 | Unclear | |
| Cagrilintide OTHER_ACTIVE_cagrilintide | 1.40 (0.73 to 2.85) | 0.60 to 3.54 | Unclear | |
| Semaglutide tablet SEMA_PO | 1.81 (0.98 to 3.20) | 0.77 to 4.07 | Unclear | |
| Exenatide extended release injection EXENER_SC | 1.81 (0.18 to 22.39) | 0.18 to 23.83 | Unclear | |
| Mazdutide injection MAZD_SC | 2.13 (0.37 to 24.27) | 0.34 to 26.03 | Unclear | |
| Efpe sc EFPE_SC | 2.30 (0.81 to 7.42) | 0.72 to 8.39 | Unclear | |
| Vk2735 sc VK2735_SC | 2.48 (0.85 to 8.94) | 0.74 to 10.23 | Unclear | |
| Alenig po ALENIG_PO | 2.57 (1.06 to 6.88) | 0.91 to 8.12 | Worse | |
| Bimasema sc BIMASEMA_SC | 2.58 (1.22 to 5.71) | 1.02 to 6.96 | Worse | |
| Liraglutide injection LIRA_SC | 2.60 (1.95 to 3.54) | 1.38 to 5.15 | Worse | |
| Semaglutide injection SEMA_SC | 2.91 (2.31 to 3.85) | 1.59 to 5.84 | Worse | |
| Dapigl sc DAPIGL_SC | 3.08 (0.77 to 17.91) | 0.71 to 19.44 | Unclear | |
| Tirzepatide injection TIRZ_SC | 3.09 (2.19 to 4.48) | 1.59 to 6.39 | Worse | |
| Orforglipron tablet ORFO_PO | 3.23 (1.94 to 5.62) | 1.53 to 7.21 | Worse | |
| Tern60 po TERN60_PO | 3.82 (0.80 to 33.54) | 0.71 to 35.81 | Unclear | |
| Retatrutide injection RETA_SC | 3.83 (1.07 to 21.46) | 0.96 to 24.02 | Worse | |
| Mari sc MARI_SC | 3.98 (0.30 to 123) | 0.28 to 134 | Unclear | |
| Loti po LOTI_PO | 4.42 (1.93 to 10.58) | 1.61 to 13.04 | Worse | |
| HRS-7535 tablet HRS7535_PO | 4.45 (0.42 to 115) | 0.40 to 123 | Unclear |
Ranking
How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.
League table
Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.
| Row versus column | PLACEBO | CT388_SC | STANDARD_CARE | OTHER_ACTIVE_bimagrumab | EXEN_SC | LIFESTYLE | ORLISTAT | DANU_PO | OTHER_ACTIVE_cagrilintide | SEMA_PO | EXENER_SC | MAZD_SC | EFPE_SC | VK2735_SC | ALENIG_PO | BIMASEMA_SC | LIRA_SC | SEMA_SC | DAPIGL_SC | TIRZ_SC | ORFO_PO | TERN60_PO | RETA_SC | MARI_SC | LOTI_PO | HRS7535_PO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLACEBO | PLACEBO | 5.00 0.53 to 61.50 | 4.29 1.95 to 10.55 | 1.87 0.55 to 8.13 | 1.80 0.02 to 170 | 1.64 0.02 to 166 | 1.16 0.47 to 3.21 | 0.76 0.13 to 2.96 | 0.72 0.35 to 1.37 | 0.55 0.31 to 1.02 | 0.55 0.04 to 5.49 | 0.47 0.04 to 2.69 | 0.43 0.13 to 1.23 | 0.40 0.11 to 1.18 | 0.39 0.15 to 0.95 | 0.39 0.18 to 0.82 | 0.38 0.28 to 0.51 | 0.34 0.26 to 0.43 | 0.32 0.06 to 1.30 | 0.32 0.22 to 0.46 | 0.31 0.18 to 0.52 | 0.26 0.03 to 1.26 | 0.26 0.05 to 0.93 | 0.25 0.01 to 3.30 | 0.23 0.09 to 0.52 | 0.22 0.01 to 2.39 |
| CT388_SC | 0.20 0.02 to 1.88 | CT388_SC | 0.85 0.06 to 9.85 | 0.38 0.02 to 5.19 | 0.32 0.00 to 56.19 | 0.34 0.00 to 55.91 | 0.23 0.02 to 2.70 | 0.14 0.01 to 2.13 | 0.14 0.01 to 1.45 | 0.11 0.01 to 1.11 | 0.11 0.00 to 2.67 | 0.09 0.00 to 1.58 | 0.09 0.01 to 1.00 | 0.08 0.00 to 0.92 | 0.08 0.01 to 0.91 | 0.08 0.01 to 0.81 | 0.08 0.01 to 0.72 | 0.07 0.01 to 0.65 | 0.06 0.00 to 0.90 | 0.06 0.01 to 0.59 | 0.06 0.00 to 0.63 | 0.05 0.00 to 0.84 | 0.05 0.00 to 0.66 | 0.05 0.00 to 1.59 | 0.04 0.00 to 0.48 | 0.04 0.00 to 1.26 |
| STANDARD_CARE | 0.23 0.09 to 0.51 | 1.17 0.10 to 16.75 | STANDARD_CARE | 0.44 0.09 to 2.32 | 0.40 0.00 to 41.57 | 0.39 0.01 to 41.56 | 0.27 0.08 to 0.95 | 0.18 0.02 to 0.85 | 0.17 0.05 to 0.45 | 0.13 0.04 to 0.35 | 0.13 0.01 to 1.42 | 0.11 0.01 to 0.75 | 0.10 0.03 to 0.36 | 0.09 0.02 to 0.37 | 0.09 0.02 to 0.30 | 0.09 0.03 to 0.26 | 0.09 0.04 to 0.19 | 0.08 0.03 to 0.18 | 0.07 0.01 to 0.38 | 0.08 0.03 to 0.16 | 0.07 0.03 to 0.18 | 0.06 0.01 to 0.35 | 0.06 0.01 to 0.29 | 0.06 0.00 to 0.90 | 0.05 0.02 to 0.17 | 0.05 0.00 to 0.66 |
| OTHER_ACTIVE_bimagrumab | 0.53 0.12 to 1.83 | 2.65 0.19 to 41.82 | 2.27 0.43 to 10.65 | OTHER_ACTIVE_bimagrumab | 0.93 0.01 to 106 | 0.86 0.01 to 107 | 0.62 0.11 to 3.10 | 0.38 0.04 to 2.45 | 0.38 0.08 to 1.53 | 0.29 0.06 to 1.16 | 0.29 0.02 to 3.91 | 0.24 0.01 to 2.18 | 0.23 0.04 to 1.20 | 0.21 0.03 to 1.14 | 0.20 0.04 to 0.96 | 0.21 0.05 to 0.68 | 0.20 0.05 to 0.71 | 0.18 0.04 to 0.61 | 0.17 0.02 to 1.13 | 0.17 0.04 to 0.61 | 0.16 0.03 to 0.63 | 0.13 0.01 to 1.04 | 0.13 0.02 to 0.82 | 0.13 0.00 to 2.39 | 0.12 0.02 to 0.54 | 0.12 0.00 to 1.79 |
| EXEN_SC | 0.56 0.01 to 48.36 | 3.10 0.02 to 431 | 2.47 0.02 to 229 | 1.08 0.01 to 109 | EXEN_SC | 1.00 0.00 to 557 | 0.66 0.01 to 65.25 | 0.41 0.00 to 45.23 | 0.40 0.00 to 36.14 | 0.31 0.00 to 27.20 | 0.31 0.00 to 45.84 | 0.26 0.00 to 28.27 | 0.25 0.00 to 23.40 | 0.22 0.00 to 23.22 | 0.21 0.00 to 20.30 | 0.21 0.00 to 19.91 | 0.21 0.00 to 20.05 | 0.19 0.00 to 17.32 | 0.18 0.00 to 17.16 | 0.18 0.00 to 16.22 | 0.17 0.00 to 15.89 | 0.13 0.00 to 16.61 | 0.14 0.00 to 14.36 | 0.13 0.00 to 25.56 | 0.13 0.00 to 11.81 | 0.12 0.00 to 18.14 |
| LIFESTYLE | 0.61 0.01 to 41.21 | 2.98 0.02 to 365 | 2.57 0.02 to 181 | 1.16 0.01 to 90.33 | 1.00 0.00 to 548 | LIFESTYLE | 0.70 0.01 to 52.06 | 0.43 0.00 to 37.91 | 0.43 0.00 to 28.97 | 0.33 0.00 to 22.74 | 0.34 0.00 to 42.56 | 0.26 0.00 to 24.68 | 0.26 0.00 to 19.58 | 0.23 0.00 to 18.79 | 0.23 0.00 to 16.51 | 0.23 0.00 to 16.48 | 0.24 0.00 to 15.91 | 0.21 0.00 to 14.19 | 0.19 0.00 to 15.86 | 0.19 0.00 to 13.44 | 0.19 0.00 to 12.46 | 0.15 0.00 to 12.65 | 0.15 0.00 to 11.32 | 0.14 0.00 to 21.30 | 0.14 0.00 to 9.33 | 0.12 0.00 to 16.61 |
| ORLISTAT | 0.86 0.31 to 2.14 | 4.40 0.37 to 59.21 | 3.66 1.06 to 13.10 | 1.62 0.32 to 8.85 | 1.51 0.02 to 153 | 1.43 0.02 to 159 | ORLISTAT | 0.64 0.09 to 3.54 | 0.62 0.18 to 1.82 | 0.48 0.15 to 1.40 | 0.46 0.03 to 5.61 | 0.39 0.03 to 3.05 | 0.37 0.08 to 1.55 | 0.34 0.07 to 1.47 | 0.33 0.08 to 1.18 | 0.33 0.09 to 1.11 | 0.33 0.12 to 0.80 | 0.30 0.10 to 0.74 | 0.27 0.04 to 1.48 | 0.28 0.09 to 0.72 | 0.27 0.08 to 0.74 | 0.22 0.02 to 1.39 | 0.22 0.03 to 1.08 | 0.21 0.01 to 3.29 | 0.19 0.05 to 0.66 | 0.19 0.01 to 2.51 |
| DANU_PO | 1.32 0.34 to 7.94 | 6.98 0.47 to 149 | 5.71 1.18 to 41.38 | 2.63 0.41 to 23.04 | 2.43 0.02 to 332 | 2.31 0.03 to 286 | 1.55 0.28 to 11.72 | DANU_PO | 0.95 0.20 to 6.38 | 0.74 0.17 to 4.76 | 0.77 0.04 to 12.51 | 0.62 0.04 to 7.34 | 0.58 0.10 to 4.41 | 0.53 0.08 to 4.24 | 0.52 0.10 to 3.70 | 0.52 0.11 to 3.24 | 0.51 0.13 to 3.12 | 0.46 0.11 to 2.74 | 0.43 0.05 to 4.02 | 0.43 0.10 to 2.59 | 0.41 0.09 to 2.70 | 0.35 0.03 to 3.67 | 0.34 0.04 to 3.01 | 0.34 0.01 to 6.63 | 0.30 0.06 to 2.11 | 0.30 0.01 to 5.77 |
| OTHER_ACTIVE_cagrilintide | 1.40 0.73 to 2.85 | 7.20 0.69 to 94.81 | 5.99 2.21 to 18.57 | 2.61 0.65 to 12.69 | 2.51 0.03 to 251 | 2.35 0.03 to 253 | 1.62 0.55 to 5.60 | 1.05 0.16 to 5.00 | OTHER_ACTIVE_cagrilintide | 0.77 0.33 to 2.01 | 0.77 0.06 to 8.46 | 0.65 0.05 to 4.47 | 0.61 0.16 to 2.18 | 0.56 0.14 to 2.05 | 0.54 0.17 to 1.66 | 0.53 0.20 to 1.51 | 0.54 0.28 to 1.07 | 0.48 0.24 to 0.98 | 0.46 0.07 to 2.24 | 0.45 0.22 to 0.98 | 0.43 0.18 to 1.08 | 0.37 0.04 to 2.05 | 0.36 0.06 to 1.65 | 0.36 0.01 to 5.12 | 0.31 0.11 to 0.96 | 0.32 0.01 to 3.78 |
| SEMA_PO | 1.81 0.98 to 3.20 | 9.18 0.90 to 116 | 7.72 2.86 to 22.31 | 3.40 0.86 to 16.36 | 3.23 0.04 to 315 | 3.01 0.04 to 318 | 2.10 0.71 to 6.68 | 1.35 0.21 to 5.97 | 1.30 0.50 to 3.05 | SEMA_PO | 0.99 0.08 to 10.33 | 0.84 0.07 to 5.17 | 0.78 0.22 to 2.55 | 0.73 0.18 to 2.41 | 0.70 0.22 to 1.99 | 0.70 0.25 to 1.76 | 0.70 0.34 to 1.30 | 0.62 0.31 to 1.13 | 0.59 0.09 to 2.61 | 0.59 0.29 to 1.11 | 0.56 0.25 to 1.17 | 0.47 0.05 to 2.49 | 0.46 0.08 to 1.85 | 0.45 0.01 to 6.23 | 0.41 0.16 to 0.94 | 0.41 0.01 to 4.60 |
| EXENER_SC | 1.81 0.18 to 22.39 | 9.36 0.37 to 324 | 7.67 0.70 to 110 | 3.41 0.26 to 60.44 | 3.26 0.02 to 506 | 2.97 0.02 to 552 | 2.17 0.18 to 31.34 | 1.31 0.08 to 23.23 | 1.29 0.12 to 17.42 | 1.01 0.10 to 12.92 | EXENER_SC | 0.82 0.03 to 19.06 | 0.78 0.06 to 11.59 | 0.71 0.05 to 11.00 | 0.70 0.06 to 10.07 | 0.70 0.06 to 9.25 | 0.69 0.07 to 8.40 | 0.62 0.06 to 7.54 | 0.57 0.03 to 9.97 | 0.58 0.06 to 7.11 | 0.56 0.05 to 7.04 | 0.45 0.02 to 9.95 | 0.46 0.03 to 7.75 | 0.45 0.01 to 16.27 | 0.40 0.03 to 5.54 | 0.40 0.01 to 12.17 |
| MAZD_SC | 2.13 0.37 to 24.27 | 10.93 0.63 to 335 | 9.29 1.34 to 116 | 4.16 0.46 to 69.07 | 3.87 0.04 to 593 | 3.79 0.04 to 572 | 2.53 0.33 to 33.21 | 1.61 0.14 to 24.39 | 1.54 0.22 to 18.57 | 1.18 0.19 to 14.10 | 1.21 0.05 to 32.56 | MAZD_SC | 0.95 0.11 to 11.52 | 0.85 0.10 to 11.96 | 0.83 0.12 to 10.22 | 0.83 0.12 to 10.25 | 0.82 0.14 to 9.27 | 0.73 0.12 to 8.56 | 0.68 0.06 to 10.82 | 0.69 0.12 to 7.99 | 0.66 0.10 to 7.60 | 0.55 0.03 to 9.83 | 0.54 0.05 to 8.56 | 0.54 0.01 to 16.67 | 0.48 0.07 to 6.10 | 0.48 0.01 to 14.46 |
| EFPE_SC | 2.30 0.81 to 7.42 | 11.59 1.00 to 183 | 9.93 2.76 to 39.94 | 4.43 0.84 to 26.98 | 4.07 0.04 to 419 | 3.88 0.05 to 432 | 2.71 0.65 to 12.34 | 1.74 0.23 to 10.33 | 1.64 0.46 to 6.18 | 1.27 0.39 to 4.61 | 1.29 0.09 to 16.07 | 1.06 0.09 to 8.85 | EFPE_SC | 0.93 0.18 to 4.44 | 0.90 0.22 to 3.72 | 0.90 0.24 to 3.41 | 0.88 0.30 to 2.90 | 0.79 0.27 to 2.53 | 0.74 0.10 to 4.72 | 0.74 0.25 to 2.51 | 0.71 0.21 to 2.54 | 0.59 0.06 to 4.50 | 0.59 0.08 to 3.33 | 0.60 0.02 to 9.78 | 0.52 0.13 to 2.16 | 0.52 0.02 to 7.37 |
| VK2735_SC | 2.48 0.85 to 8.94 | 12.94 1.08 to 201 | 10.89 2.72 to 50.01 | 4.77 0.88 to 31.21 | 4.46 0.04 to 479 | 4.37 0.05 to 484 | 2.94 0.68 to 14.76 | 1.89 0.24 to 11.87 | 1.79 0.49 to 7.39 | 1.38 0.41 to 5.59 | 1.40 0.09 to 18.30 | 1.18 0.08 to 10.13 | 1.08 0.23 to 5.62 | VK2735_SC | 0.97 0.22 to 4.56 | 0.97 0.25 to 4.22 | 0.96 0.31 to 3.52 | 0.85 0.28 to 3.06 | 0.81 0.10 to 5.36 | 0.80 0.25 to 3.02 | 0.77 0.23 to 2.98 | 0.64 0.06 to 4.97 | 0.64 0.09 to 3.88 | 0.64 0.02 to 10.56 | 0.57 0.14 to 2.52 | 0.57 0.02 to 8.62 |
| ALENIG_PO | 2.57 1.06 to 6.88 | 13.19 1.09 to 187 | 11.10 3.33 to 40.80 | 4.89 1.04 to 27.68 | 4.68 0.05 to 484 | 4.27 0.06 to 491 | 3.01 0.84 to 12.07 | 1.94 0.27 to 10.40 | 1.84 0.60 to 5.73 | 1.43 0.50 to 4.53 | 1.44 0.10 to 16.53 | 1.20 0.10 to 8.49 | 1.12 0.27 to 4.56 | 1.03 0.22 to 4.51 | ALENIG_PO | 1.00 0.30 to 3.32 | 0.99 0.38 to 2.65 | 0.88 0.35 to 2.40 | 0.82 0.13 to 4.50 | 0.84 0.32 to 2.31 | 0.80 0.28 to 2.34 | 0.67 0.06 to 4.20 | 0.66 0.10 to 3.29 | 0.65 0.02 to 9.86 | 0.58 0.17 to 2.07 | 0.58 0.02 to 7.29 |
| BIMASEMA_SC | 2.58 1.22 to 5.71 | 13.22 1.23 to 166 | 11.11 3.80 to 36.36 | 4.84 1.48 to 20.69 | 4.67 0.05 to 438 | 4.30 0.06 to 479 | 3.02 0.90 to 10.94 | 1.92 0.31 to 9.28 | 1.87 0.66 to 4.92 | 1.42 0.57 to 3.93 | 1.43 0.11 to 16.08 | 1.21 0.10 to 8.13 | 1.11 0.29 to 4.16 | 1.03 0.24 to 4.06 | 1.00 0.30 to 3.32 | BIMASEMA_SC | 0.99 0.45 to 2.22 | 0.89 0.43 to 1.82 | 0.84 0.13 to 4.15 | 0.83 0.37 to 1.90 | 0.80 0.31 to 2.05 | 0.67 0.07 to 3.90 | 0.67 0.10 to 2.94 | 0.64 0.02 to 9.16 | 0.58 0.19 to 1.84 | 0.59 0.02 to 7.23 |
| LIRA_SC | 2.60 1.95 to 3.54 | 13.27 1.39 to 163 | 11.11 5.14 to 28.24 | 4.89 1.40 to 21.74 | 4.65 0.05 to 437 | 4.25 0.06 to 434 | 3.01 1.25 to 8.42 | 1.98 0.32 to 7.92 | 1.86 0.93 to 3.52 | 1.44 0.77 to 2.90 | 1.45 0.12 to 14.57 | 1.22 0.11 to 7.36 | 1.14 0.34 to 3.33 | 1.05 0.28 to 3.26 | 1.01 0.38 to 2.60 | 1.01 0.45 to 2.22 | LIRA_SC | 0.89 0.63 to 1.25 | 0.85 0.14 to 3.50 | 0.84 0.54 to 1.30 | 0.80 0.44 to 1.47 | 0.68 0.08 to 3.46 | 0.68 0.12 to 2.54 | 0.65 0.02 to 8.83 | 0.59 0.24 to 1.46 | 0.59 0.02 to 6.42 |
| SEMA_SC | 2.91 2.31 to 3.85 | 14.73 1.55 to 182 | 12.48 5.65 to 31.85 | 5.47 1.65 to 23.45 | 5.20 0.06 to 498 | 4.81 0.07 to 479 | 3.39 1.34 to 9.54 | 2.20 0.36 to 8.82 | 2.08 1.02 to 4.17 | 1.60 0.89 to 3.18 | 1.61 0.13 to 16.00 | 1.37 0.12 to 8.15 | 1.26 0.39 to 3.71 | 1.18 0.33 to 3.63 | 1.14 0.42 to 2.88 | 1.13 0.55 to 2.31 | 1.12 0.80 to 1.59 | SEMA_SC | 0.95 0.16 to 3.91 | 0.94 0.65 to 1.39 | 0.90 0.50 to 1.63 | 0.76 0.09 to 3.74 | 0.75 0.13 to 2.80 | 0.73 0.02 to 9.72 | 0.66 0.27 to 1.60 | 0.66 0.03 to 7.03 |
| DAPIGL_SC | 3.08 0.77 to 17.91 | 16.08 1.11 to 323 | 13.43 2.62 to 89.81 | 6.01 0.89 to 55.94 | 5.64 0.06 to 740 | 5.39 0.06 to 686 | 3.71 0.68 to 26.51 | 2.34 0.25 to 20.74 | 2.17 0.45 to 13.91 | 1.70 0.38 to 11.22 | 1.76 0.10 to 29.85 | 1.47 0.09 to 17.63 | 1.34 0.21 to 10.34 | 1.24 0.19 to 9.68 | 1.22 0.22 to 7.91 | 1.19 0.24 to 7.87 | 1.17 0.29 to 6.96 | 1.05 0.26 to 6.11 | DAPIGL_SC | 0.99 0.24 to 5.62 | 0.96 0.22 to 5.72 | 0.81 0.06 to 8.34 | 0.80 0.09 to 7.02 | 0.78 0.02 to 17.46 | 0.70 0.14 to 4.71 | 0.72 0.02 to 14.12 |
| TIRZ_SC | 3.09 2.19 to 4.48 | 15.58 1.69 to 199 | 13.14 6.10 to 32.76 | 5.84 1.65 to 25.87 | 5.64 0.06 to 527 | 5.17 0.07 to 503 | 3.61 1.38 to 10.72 | 2.35 0.39 to 9.74 | 2.22 1.02 to 4.62 | 1.71 0.90 to 3.50 | 1.74 0.14 to 17.48 | 1.46 0.13 to 8.69 | 1.35 0.40 to 4.08 | 1.25 0.33 to 3.97 | 1.19 0.43 to 3.15 | 1.20 0.53 to 2.70 | 1.19 0.77 to 1.84 | 1.06 0.72 to 1.54 | 1.01 0.18 to 4.23 | TIRZ_SC | 0.96 0.51 to 1.80 | 0.81 0.09 to 3.97 | 0.80 0.14 to 3.04 | 0.78 0.02 to 9.99 | 0.70 0.28 to 1.77 | 0.70 0.03 to 7.83 |
| ORFO_PO | 3.23 1.94 to 5.62 | 16.48 1.59 to 217 | 13.87 5.51 to 39.11 | 6.08 1.58 to 29.15 | 5.84 0.06 to 540 | 5.29 0.08 to 567 | 3.75 1.35 to 11.91 | 2.46 0.37 to 10.75 | 2.33 0.92 to 5.42 | 1.78 0.85 to 4.07 | 1.80 0.14 to 19.04 | 1.50 0.13 to 9.71 | 1.41 0.39 to 4.69 | 1.30 0.34 to 4.39 | 1.25 0.43 to 3.63 | 1.25 0.49 to 3.23 | 1.24 0.68 to 2.27 | 1.12 0.61 to 1.98 | 1.05 0.17 to 4.62 | 1.04 0.55 to 1.96 | ORFO_PO | 0.84 0.09 to 4.43 | 0.84 0.14 to 3.42 | 0.82 0.02 to 11.50 | 0.73 0.27 to 1.99 | 0.74 0.03 to 8.35 |
| TERN60_PO | 3.82 0.80 to 33.54 | 20.75 1.20 to 549 | 17.11 2.84 to 167 | 7.65 0.96 to 94.57 | 7.54 0.06 to 939 | 6.85 0.08 to 1126 | 4.53 0.72 to 48.94 | 2.90 0.27 to 37.78 | 2.73 0.49 to 26.51 | 2.14 0.40 to 20.60 | 2.22 0.10 to 49.94 | 1.83 0.10 to 30.95 | 1.69 0.22 to 18.11 | 1.55 0.20 to 16.94 | 1.49 0.24 to 15.54 | 1.49 0.26 to 14.65 | 1.47 0.29 to 13.05 | 1.31 0.27 to 11.50 | 1.24 0.12 to 17.54 | 1.24 0.25 to 11.27 | 1.19 0.23 to 11.10 | TERN60_PO | 1.00 0.10 to 12.71 | 1.02 0.02 to 27.37 | 0.87 0.14 to 8.93 | 0.89 0.02 to 21.57 |
| RETA_SC | 3.83 1.07 to 21.46 | 20.25 1.53 to 407 | 16.93 3.43 to 110 | 7.52 1.22 to 62.29 | 7.15 0.07 to 894 | 6.87 0.09 to 859 | 4.58 0.93 to 32.60 | 2.93 0.33 to 25.07 | 2.76 0.60 to 17.28 | 2.15 0.54 to 12.85 | 2.20 0.13 to 35.55 | 1.85 0.12 to 21.76 | 1.68 0.30 to 11.77 | 1.57 0.26 to 10.89 | 1.50 0.30 to 10.24 | 1.49 0.34 to 9.55 | 1.48 0.39 to 8.34 | 1.33 0.36 to 7.53 | 1.26 0.14 to 11.03 | 1.25 0.33 to 7.02 | 1.20 0.29 to 6.98 | 1.00 0.08 to 9.94 | RETA_SC | 1.00 0.03 to 21.67 | 0.88 0.19 to 5.70 | 0.89 0.03 to 15.71 |
| MARI_SC | 3.98 0.30 to 123 | 21.36 0.63 to 1309 | 17.46 1.11 to 627 | 7.61 0.42 to 322 | 7.48 0.04 to 1836 | 7.12 0.05 to 2061 | 4.81 0.30 to 161 | 2.94 0.15 to 119 | 2.80 0.20 to 91.07 | 2.21 0.16 to 70.49 | 2.25 0.06 to 130 | 1.84 0.06 to 86.66 | 1.67 0.10 to 62.08 | 1.57 0.09 to 57.61 | 1.53 0.10 to 53.64 | 1.57 0.11 to 53.99 | 1.54 0.11 to 49.21 | 1.36 0.10 to 43.72 | 1.29 0.06 to 56.88 | 1.29 0.10 to 41.24 | 1.22 0.09 to 40.51 | 0.98 0.04 to 45.27 | 1.00 0.05 to 39.78 | MARI_SC | 0.91 0.06 to 31.01 | 0.89 0.01 to 59.78 |
| LOTI_PO | 4.42 1.93 to 10.58 | 22.68 2.08 to 299 | 18.98 6.01 to 65.41 | 8.40 1.87 to 46.87 | 7.79 0.08 to 824 | 7.40 0.11 to 753 | 5.20 1.51 to 19.53 | 3.34 0.47 to 16.49 | 3.20 1.04 to 9.19 | 2.44 1.06 to 6.08 | 2.49 0.18 to 28.67 | 2.08 0.16 to 15.01 | 1.92 0.46 to 7.47 | 1.77 0.40 to 7.10 | 1.72 0.48 to 5.81 | 1.71 0.54 to 5.34 | 1.70 0.69 to 4.18 | 1.52 0.62 to 3.68 | 1.43 0.21 to 7.07 | 1.43 0.56 to 3.57 | 1.37 0.50 to 3.69 | 1.15 0.11 to 7.10 | 1.14 0.18 to 5.30 | 1.10 0.03 to 16.83 | LOTI_PO | 1.01 0.03 to 12.14 |
| HRS7535_PO | 4.45 0.42 to 115 | 23.55 0.79 to 1354 | 18.95 1.52 to 568 | 8.68 0.56 to 308 | 8.60 0.06 to 1927 | 8.28 0.06 to 1805 | 5.16 0.40 to 166 | 3.31 0.17 to 113 | 3.14 0.26 to 88.37 | 2.47 0.22 to 68.74 | 2.52 0.08 to 124 | 2.06 0.07 to 88.03 | 1.92 0.14 to 59.02 | 1.76 0.12 to 54.17 | 1.73 0.14 to 51.87 | 1.71 0.14 to 47.28 | 1.70 0.16 to 45.32 | 1.52 0.14 to 39.14 | 1.39 0.07 to 49.61 | 1.42 0.13 to 37.04 | 1.35 0.12 to 38.16 | 1.12 0.05 to 41.84 | 1.13 0.06 to 39.11 | 1.12 0.02 to 76.55 | 0.99 0.08 to 29.69 | HRS7535_PO |
Heterogeneity, fit and convergence
Bayesian random effects (primary)
Inconsistency
Do trials comparing two treatments directly agree with the indirect evidence through other treatments?
No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.
Small study effects
A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.
Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- NoteOutcome assessment, time point: selected time points span 4.29 to 193 weeks
- NoteOutcome assessment, analysis set: mixed: randomized 10, safety 34
- NoteOutcome assessment, definition: mixed: deaths in safety population 1, nausea 1, not stated 41, participants with serious treatment emergent adverse events 1
- NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 43, while_on_treatment 1
- NoteOutcome assessment, intercurrent events (rescue): mixed: not stated 43, treatment_policy 1
- NoteRisk of bias, blinding: mixed: double_blind 39, open_label 4, single_blind 1
- NoteRisk of bias, funding: mixed: industry 39, mixed 2, non_industry 2, not_reported 1
- NoteData handling, input conversions: arms_combined 23, nonserious_only 38, printed_denominator 8
| Trial | analysis set | time weeks | definition | adjudicated | instrument | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STEP 10 | safety | 57 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | Adults with obesity and prediabetes; diabetes excluded |
| TOGETHER-PsO | safety | 36 | not stated | not stated | not stated | not stated | not stated | not stated | open_label | industry | 2024 | adults; moderate to severe plaque psoriasis; PASI 12 or more; BMI 30 or more, or 27 to 30 with comorbidity |
| NCT04081337 | randomized | 22 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2020 | age 18 to 60; BMI 30 to 45; no diabetes; at least one metabolic impairment |
| SURMOUNT-5 | safety | 72 | not stated | not stated | not stated | not stated | not stated | not stated | open_label | industry | 2023 | adults; BMI 30 or more, or 27 with complication; no diabetes |
| STEP 1 | safety | 75 | not stated | not stated | not stated | not stated | while_on_treatment | treatment_policy | double_blind | industry | 2018 | adults; BMI 30 or more, or 27 or more with a weight related condition; no diabetes; HbA1c below 6.5 percent |
| STEP 5 | safety | 111 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2018 | age 18 or older; BMI 30 or more, or 27 or more with comorbidity; no diabetes; HbA1c below 6.5 percent |
| NCT04707313 | safety | 37 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | age 18 to 75; BMI 30 or higher; no diabetes; stable weight |
| NCT04311411 | safety | 10 | nausea | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2020 | adults 18 to 65, BMI 27 to 50, no diabetes, HbA1c below 6.5 |
| NCT03041792 | safety | 10.43 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2017 | age 18 to 75; BMI 30 to 40; no diabetes; HbA1c below 6.5 percent |
| BARI-STEP | randomized | 74 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | mixed | 2022 | age 18 to 65; at least 1 year after primary bypass or sleeve; less than 20 percent weight loss from surgery |
| NCT05579977 | safety | 28 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2022 | age 18 to 75; T2D cohort on metformin, HbA1c 7.0 to 10.0, BMI 23 or more; obesity cohort BMI 30 or more without diabetes |
| BARIOPTIMISE | randomized | 28 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | mixed | 2018 | adults at least 1 year after RYGB or sleeve gastrectomy with 20 percent or less weight loss and suboptimal GLP-1 response |
| VENTURE | safety | 19 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2023 | age over 18; BMI 30 or more, or 27 or more with comorbidity; BMI 50 or less; no diabetes |
| NCT05616013 | safety | 104 | not stated | not stated | not stated | not stated | not stated | not stated | open_label | industry | 2022 | adults 18 to 80; BMI 30 or more, or 27 or more with comorbidity; no diabetes (HbA1c below 6.5 percent); weight below 150 kg |
| NCT02075281 | safety | 26 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2014 | age 18 to 64 years; BMI 30 to 42, or 27 to 30 with comorbidity; FPG below 7 mmol/L; HbA1c 6.5 percent or less; no diabetes |
| NCT02160990 | randomized | 4.29 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | non_industry | 2014 | Adults; BMI 30 to 40; accelerated gastric emptying; no diabetes |
| ACCESS | safety | 36 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2024 | age 18 to 79; BMI 30 or more, or 27 or more with comorbidity; HbA1c below 6.5 percent; weight above 80 kg; no diabetes |
| STEP 3 | safety | 75 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2018 | BMI 30 or more, or 27 with comorbidity; no type 2 diabetes |
| NCT02647944 | randomized | 16 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | not_reported | 2015 | adults with obesity |
| SURMOUNT-1 | safety | 193 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2019 | age 18 or older; BMI 30 or more, or 27 or more with a weight related complication; no diabetes |
| NCT04478708 | safety | 29.43 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2020 | age 18 to 65; BMI 30 to 40; HbA1c at most 6.5 or fasting glucose below 125 mg/dL |
| Dapalost | safety | 24 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2014 | age 18 to 70; BMI 30 to 45 kg/m2; no diabetes |
| NCT00781937 | safety | 57 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2008 | BMI 30 or more or 27 with comorbidity; no diabetes; at least 5 percent loss on run in |
| STEP7 | safety | 51 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2020 | age 18 or older; BMI 30 or more, or 27 or more with a weight related comorbidity including T2D |
| STABLE Wt Loss | randomized | 60 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2022 | age 18 to 70; BMI 30 or more, or 27 or more with comorbidity; no diabetes; HbA1c 6.5 percent or less |
| OASIS 1 | safety | 75 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | overweight or obesity |
| NCT03856047 | safety | 26 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2019 | age 18 or older; BMI 30 or more, or 27 or more with hypertension or dyslipidemia; no diabetes |
| NCT05623839 | safety | 27 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2022 | age 18 to 70; BMI 27 to 50; HbA1c below 6.5 percent; no diabetes |
| STEP 8 | safety | 75 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2019 | age 18 or older; BMI 30 or higher, or 27 with a weight related comorbidity; no type 2 diabetes |
| NCT04881760 | safety | 52 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | 18 to 75 years; BMI 30 or more, or 27 to less than 30 with weight related complication; no type 2 diabetes |
| STRIVE | safety | 104 | not stated | not stated | not stated | not stated | not stated | not stated | open_label | industry | 2017 | age 18 to 75; BMI 35 or more plus prediabetes, T2D, hypertension or sleep apnea; no insulin or GLP-1 RA |
| ATTAIN-1 | safety | 74 | deaths in safety population | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2023 | adults BMI 30 or more, or 27 or more with a weight related complication, without diabetes |
| TOGETHER-PsA | safety | 36 | not stated | not stated | not stated | not stated | not stated | not stated | single_blind | industry | 2024 | age 18 to 80; active psoriatic arthritis; BMI 30 or more, or 27 to 30 with a weight related comorbidity |
| DREAM | randomized | 16 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2023 | age 18 to 75; BMI 30 or more; no diabetes, HbA1c below 48 mmol/mol |
| STEP 6 | safety | 75 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2019 | |
| SURMOUNT-3 | safety | 76 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | age 18 or older; BMI 30 or more, or 27 or more with comorbidity; no diabetes; at least 5 percent loss in lead in |
| NCT06250946 | safety | 36 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2024 | age 18 to 65; BMI 28 to 40; no diabetes, HbA1c below 6.5 percent |
| NCT01557166 | safety | 34 | participants with serious treatment emergent adverse events | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2012 | age 18 to 64; BMI 30 or more; AHI 15 or more; no diabetes; unable or unwilling to use CPAP |
| NCT02453711 | safety | 59 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2015 | BMI 30 or more without diabetes |
| NCT05051579 | safety | 38 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | adults BMI 30 or more, or 27 to 30 with a weight related complication, without diabetes |
| FALCON | safety | 16 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2025 | age 18 to 75; BMI 27 to below 50 with comorbidity if below 30; HbA1c below 6.5 |
| NCT04838405 | randomized | 24 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | age 18 to 65, BMI 25 or more (30 or more in cohorts 7 and 8), no diabetes |
| S002970 | randomized | 26.07 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | non_industry | 2019 | age 20 to 75; BMI 27 to 40; impaired glucose tolerance by OGTT; no diabetes |
| S003067 | randomized | 52 | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2007 | age 18 to 65; BMI 30 to 40; FPG below 7 mmol/L; no diabetes |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| TOGETHER-PsO | A1 | STANDARD_CARE | 36 | arm, events | 0 / 134 | printed_denominator | R0014237:Table 3 | ||
| TOGETHER-PsO | A2 | TIRZ_SC | 36 | arm, events | 18 / 138 | printed_denominator | R0014237:Table 3 | ||
| NCT04081337 | A1 | PLACEBO | 22 | arm, events | 4 / 28 | R0004227:Supplement Table S1 | |||
| NCT04081337 | A2 | TIRZ_SC | 22 | arm, events | 10 / 27 | R0004227:Supplement Table S1 | |||
| SURMOUNT-5 | A1 | TIRZ_SC | 72 | arm, events | 101 / 375 | nonserious_only | registry:adverse_events | ||
| SURMOUNT-5 | A2 | SEMA_SC | 72 | arm, events | 107 / 376 | nonserious_only | registry:adverse_events | ||
| STEP 1 | A1 | SEMA_SC | 75 | arm, events | 306 / 1,306 | R0023399:Table 3 | |||
| STEP 1 | A2 | PLACEBO | 75 | arm, events | 62 / 655 | R0023399:Table 3 | |||
| STEP 5 | A1 | SEMA_SC | 111 | arm, events | 47 / 152 | R0021896:Table 3 | |||
| STEP 5 | A2 | PLACEBO | 111 | arm, events | 17 / 152 | R0021896:Table 3 | |||
| NCT04707313 | A11+A12+A13 | DANU_PO | 37 | arm, events | 14 / 110 | arms_combined | R0005921:Table 2 | ||
| NCT04707313 | A2 | PLACEBO | 37 | arm, events | 2 / 19 | R0005921:Table 2 | |||
| NCT04311411 | A1 | PLACEBO | 10 | arm, events | 0 / 39 | nonserious_only | registry:adverse_events | ||
| NCT04311411 | A2 | LIRA_SC | 10 | arm, events | 5 / 38 | nonserious_only | registry:adverse_events | ||
| NCT04311411 | A3 | TIRZ_SC | 10 | arm, events | 7 / 37 | nonserious_only | registry:adverse_events | ||
| NCT03041792 | A1 | LIRA_SC | 10.43 | arm, events | 9 / 32 | R0023522:Table 2 | |||
| NCT03041792 | A2 | PLACEBO | 10.43 | arm, events | 3 / 29 | R0023522:Table 2 | |||
| BARI-STEP | A1 | PLACEBO | 74 | arm, events | 8 / 35 | R0014003:Table 3 | |||
| BARI-STEP | A2 | SEMA_SC | 74 | arm, events | 13 / 35 | R0014003:Table 3 | |||
| NCT05579977 | A1+A8 | PLACEBO | 28 | arm, events | 6 / 139 | arms_combined | R0004106:Table 2 | ||
| NCT05579977 | A10+A11+A12+A13+A2+A3+A4+A5+A6+A9 | LOTI_PO | 28 | arm, events | 106 / 690 | arms_combined | R0004106:Table 2 | ||
| NCT05579977 | A7 | SEMA_PO | 28 | arm, events | 4 / 73 | R0004106:Table 2 | |||
| BARIOPTIMISE | A1 | PLACEBO | 28 | arm, events | 2 / 35 | R0017334:Table 3 | |||
| BARIOPTIMISE | A2 | LIRA_SC | 28 | arm, events | 9 / 35 | R0017334:Table 3 | |||
| VENTURE | A1 | PLACEBO | 19 | arm, events | 4 / 35 | R0011224:Table 3 | |||
| VENTURE | A2+A3+A4+A5 | VK2735_SC | 19 | arm, events | 36 / 141 | arms_combined | R0011224:Table 3 | ||
| NCT05616013 | A3 | OTHER_ACTIVE_bimagrumab | 104 | arm, events | 3 / 57 | nonserious_only | registry:adverse_events | ||
| NCT05616013 | A4+A5 | SEMA_SC | 104 | arm, events | 27 / 113 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT05616013 | A6+A7+A8+A9 | BIMASEMA_SC | 104 | arm, events | 49 / 225 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT02075281 | A1 | PLACEBO | 26 | arm, events | 5 / 60 | R0011218:Table 3 | |||
| NCT02075281 | A2+A3+A4+A5 | EFPE_SC | 26 | arm, events | 43 / 237 | arms_combined | R0011218:Table 3 | ||
| STEP 10 | A1 | SEMA_SC | 57 | arm, events | 25 / 138 | nonserious_only | registry:adverse_events | ||
| STEP 10 | A2 | PLACEBO | 57 | arm, events | 0 / 69 | nonserious_only | registry:adverse_events | ||
| NCT02160990 | A1 | PLACEBO | 4.29 | arm, events | 0 / 10 | R0020690:Results | |||
| NCT02160990 | A2 | EXEN_SC | 4.29 | arm, events | 0 / 10 | R0020690:Results | |||
| ACCESS | A1+A2+A3 | ALENIG_PO | 36 | arm, events | 57 / 174 | arms_combined | R0000892:Table 2 | ||
| ACCESS | A4 | PLACEBO | 36 | arm, events | 8 / 56 | R0000892:Table 2 | |||
| STEP 3 | A1 | SEMA_SC | 75 | arm, events | 150 / 407 | nonserious_only | registry:adverse_events | ||
| STEP 3 | A2 | PLACEBO | 75 | arm, events | 50 / 204 | nonserious_only | registry:adverse_events | ||
| NCT02647944 | A1 | LIRA_SC | 16 | arm, events | 2 / 19 | nonserious_only | registry:adverse_events | ||
| NCT02647944 | A2 | PLACEBO | 16 | arm, events | 2 / 21 | nonserious_only | registry:adverse_events | ||
| SURMOUNT-1 | A1 | PLACEBO | 193 | arm, events | 38 / 643 | nonserious_only | registry:adverse_events | ||
| SURMOUNT-1 | A2+A3+A4 | TIRZ_SC | 193 | arm, events | 310 / 1,896 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT04478708 | A10+A11+A14+A9 | MARI_SC | 29.43 | arm, events | 3 / 30 | printed_denominator;nonserious_only;printed_denominator;arms_combined | R0006305:Table 2 | ||
| NCT04478708 | A15+A8 | PLACEBO | 29.43 | arm, events | 0 / 9 | nonserious_only;printed_denominator;printed_denominator;arms_combined | registry:adverse_events | ||
| Dapalost | A1 | EXENER_SC | 24 | arm, events | 2 / 25 | R0025627:Table 3 | |||
| Dapalost | A2 | PLACEBO | 24 | arm, events | 1 / 25 | R0025627:Table 3 | |||
| NCT00781937 | A1 | LIRA_SC | 57 | arm, events | 57 / 212 | nonserious_only | registry:adverse_events | ||
| NCT00781937 | A2 | PLACEBO | 57 | arm, events | 26 / 210 | nonserious_only | registry:adverse_events | ||
| STEP7 | A1 | SEMA_SC | 51 | arm, events | 29 / 249 | nonserious_only | registry:adverse_events | ||
| STEP7 | A2 | PLACEBO | 51 | arm, events | 7 / 126 | nonserious_only | registry:adverse_events | ||
| STABLE Wt Loss | A1 | SEMA_SC | 60 | arm, events | 38 / 72 | R0013679:Table 4 | |||
| STABLE Wt Loss | A2 | PLACEBO | 60 | arm, events | 8 / 48 | R0013679:Table 4 | |||
| OASIS 1 | A1 | SEMA_PO | 75 | arm, events | 92 / 334 | nonserious_only | registry:adverse_events | ||
| OASIS 1 | A2 | PLACEBO | 75 | arm, events | 50 / 333 | nonserious_only | registry:adverse_events | ||
| NCT03856047 | A1+A2+A3+A4+A5 | OTHER_ACTIVE_cagrilintide | 26 | arm, events | 66 / 506 | arms_combined | R0017871:Table 3 | ||
| NCT03856047 | A6 | LIRA_SC | 26 | arm, events | 26 / 99 | R0017871:Table 3 | |||
| NCT03856047 | A7 | PLACEBO | 26 | arm, events | 7 / 101 | R0017871:Table 3 | |||
| NCT05623839 | A1 | PLACEBO | 27 | arm, events | 1 / 8 | R0013210:Supplement Table S2 | |||
| NCT05623839 | A2+A3 | MAZD_SC | 27 | arm, events | 6 / 24 | arms_combined | R0013210:Supplement Table S2 | ||
| STEP 8 | A1 | SEMA_SC | 75 | arm, events | 49 / 126 | nonserious_only | registry:adverse_events | ||
| STEP 8 | A2 | LIRA_SC | 75 | arm, events | 40 / 127 | nonserious_only | registry:adverse_events | ||
| STEP 8 | A3 | PLACEBO | 75 | arm, events | 20 / 85 | nonserious_only | registry:adverse_events | ||
| NCT04881760 | A1 | PLACEBO | 52 | arm, events | 2 / 70 | nonserious_only | registry:adverse_events | ||
| NCT04881760 | A2+A3+A4+A5+A6+A7 | RETA_SC | 52 | arm, events | 30 / 268 | nonserious_only;arms_combined | registry:adverse_events | ||
| STRIVE | A1 | STANDARD_CARE | 104 | arm, events | 4 / 132 | R0020855:Table 4 | |||
| STRIVE | A2 | LIRA_SC | 104 | arm, events | 84 / 260 | R0020855:Table 4 | |||
| ATTAIN-1 | A1 | PLACEBO | 74 | arm, events | 88 / 949 | nonserious_only | registry:adverse_events | ||
| ATTAIN-1 | A2+A3+A4 | ORFO_PO | 74 | arm, events | 557 / 2,178 | nonserious_only;arms_combined | registry:adverse_events | ||
| TOGETHER-PsA | A1 | STANDARD_CARE | 36 | arm, events | 4 / 132 | printed_denominator | R0018951:Table 3 | ||
| TOGETHER-PsA | A2 | TIRZ_SC | 36 | arm, events | 23 / 138 | printed_denominator | R0018951:Table 3 | ||
| DREAM | A1 | PLACEBO | 16 | arm, events | 2 / 18 | R0011013:Table 3 | |||
| DREAM | A2+A3 | DAPIGL_SC | 16 | arm, events | 11 / 36 | arms_combined | R0011013:Table 3 | ||
| STEP 6 | A1+A2 | SEMA_SC | 75 | arm, events | 71 / 300 | nonserious_only;arms_combined | registry:adverse_events | ||
| STEP 6 | A3 | PLACEBO | 75 | arm, events | 3 / 101 | nonserious_only | registry:adverse_events | ||
| SURMOUNT-3 | A1 | TIRZ_SC | 76 | arm, events | 66 / 287 | R0007405:Table 3 | |||
| SURMOUNT-3 | A2 | PLACEBO | 76 | arm, events | 20 / 292 | R0007405:Table 3 | |||
| NCT06250946 | A1 | PLACEBO | 36 | arm, events | 0 / 46 | R0001289:Supplement Table 6 | |||
| NCT06250946 | A2+A3+A4+A5 | HRS7535_PO | 36 | arm, events | 5 / 189 | arms_combined | R0001289:Supplement Table 6 | ||
| NCT01557166 | A1 | LIRA_SC | 34 | arm, events | 21 / 180 | R0026203:Table 2 | |||
| NCT01557166 | A2 | PLACEBO | 34 | arm, events | 6 / 179 | R0026203:Table 2 | |||
| NCT02453711 | A1+A2+A3+A4+A5+A6+A7 | SEMA_SC | 59 | arm, events | 151 / 718 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT02453711 | A8 | LIRA_SC | 59 | arm, events | 24 / 103 | nonserious_only | registry:adverse_events | ||
| NCT02453711 | A9 | PLACEBO | 59 | arm, events | 6 / 136 | nonserious_only | registry:adverse_events | ||
| NCT05051579 | A1+A2+A3+A4+A5+A6 | ORFO_PO | 38 | arm, events | 54 / 222 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT05051579 | A7 | PLACEBO | 38 | arm, events | 3 / 50 | nonserious_only | registry:adverse_events | ||
| FALCON | A1 | PLACEBO | 16 | arm, events | 1 / 33 | R0004304:Table 2 | |||
| FALCON | A2+A3+A4+A5 | TERN60_PO | 16 | arm, events | 16 / 134 | arms_combined | R0004304:Table 2 | ||
| NCT04838405 | A1 | PLACEBO | 24 | arm, events | 2 / 10 | R0007991:Table 2 | |||
| NCT04838405 | A2+A3+A4+A5+A6 | CT388_SC | 24 | arm, events | 1 / 30 | arms_combined | R0007991:Table 2 | ||
| S002970 | A1 | LIFESTYLE | 26.07 | arm, events | 0 / 22 | R0008860:Supplementary Table SI | |||
| S002970 | A2 | LIRA_SC | 26.07 | arm, events | 0 / 17 | R0008860:Supplementary Table SI | |||
| S003067 | A1 | PLACEBO | 52 | arm, events | 12 / 98 | R0025439:Table 2 | |||
| S003067 | A2+A3+A4+A5 | LIRA_SC | 52 | arm, events | 64 / 371 | arms_combined | R0025439:Table 2 | ||
| S003067 | A6 | ORLISTAT | 52 | arm, events | 7 / 95 | R0025439:Table 2 |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.